Aptahem’s patent family 2 in Europe has been finalized by validation in the 11 countries where applied

Aptahem AB (publ) announces today that in all countries in Europe where the company has applied for patent protection now have validated and approved the patent family 2. The patent has been published with patent number 3691655.

With these validations of the approved patent application in Europe, the company's drug candidate Apta-1 is now protected within patent family 2 in the following countries: Sweden, Great Britain, Germany, France, Spain, Italy, The Netherlands, Austria, Poland, Turkey and Switzerland. The patent protection is valid until the end of 2038.

CEO Mikael Lindstam comments:
"Even if we expected this approval, it is always positive news to receive the confirmation that the validation in Europe has been finalized and the 11 chosen important nations are great markets with large business potential."

For further information:
Aptahem AB
Mikael Lindstam, CEO
Tel: +46 (0)766-33 36 99
E-mail: [email protected]

About Sepsis
Sepsis is today considered a world health problem and affects 49 million people worldwide each year, of which 11 million die. In Europe alone, over 1 million people are estimated to be affected by sepsis on a yearly basis*. There is currently no specific treatment for sepsis, but instead the underlying symptoms are treated with antibiotics, fluids and oxygen.

* Rudd KE, Johnson SC, Agesa KM, Shackelford KA, Tsoi D, Kievlan DR, Colombara DV, Ikuta KS, Kissoon N, Finfer S, Fleischmann-Struzek C, Machado FR, Reinhart KK, Rowan K, Seymour CW, Watson RS, West TE, Marinho F, Hay SI, Lozano R, Lopez AD, Angus DC, Murray CJL, Naghavi M. Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study. Lancet. 2020 Jan 18;395(10219):200-211. doi: 10.1016/S0140-6736(19)32989-7. PMID: 31954465; PMCID: PMC6970225.

About Aptahem
Aptahem AB (APTA) is a biotechnology company that develops aptamer-based pharmaceuticals for the treatment of life-threatening conditions in which a combination of coagulation and inflammation are involved. The company's primary pharmaceutical candidate, Apta-1, is being developed with the aim of preventing the high mortality rate caused by organ and tissue damage in sepsis patients, among others. The company possesses patent protection in strategic target markets and actively seeks business development opportunities with potential collaborators.